S2 Table. Sensitivity analyses with different cutoffs to define the summary estimate of the TURN (n=112 drug-indication groups).

| | TURN: frequency of missing doses (days) | | | | | | Always |
|----------|---|---------|---------|--------|--------|--------|------------|
| | 1/month | 2/month | 3/month | 1/week | 2/week | 3/week | acceptable |
| Cutoff * | -n | -n | -n | -n | -n | -n | -n |
| 50% -n | 5 a | 5 | 10 | 35 | 20 | 13 | 24 |
| 60% -n | 10 | 10 | 16 | 31 | 17 | 9 | 19 |
| 75% -n | 22 | 16 | 25 | 20 | 11 | 8 | 10 |
| 80% -n | 28 | 21 | 21 | 22 | 4 | 8 | 8 |
| 90% -n | 56 | 17 | 11 | 17 | 6 | 0 | 5 b |

n corresponds to the number of drug-indication groups

^{*} the cutoff corresponds to the percentage used to define the summary estimate of the TURN (e.g., for the cutoff highlighted in grey [75%] in the primary analysis, the summary TURN was defined as response category over which 75% of physicians' estimates were located).

^a Drug-indication groups for which the TURN is "1 day/month" whatever the cut-off: antiepileptics in epilepsy, corticosteroids for prevention against graft rejection, glucocorticoids in adrenal insufficiency, hormonal contraceptives for systemic use, immunosuppressants for prevention against graft rejection

^b Drug-indication groups for which the TURN is "always acceptable" whatever the cut-off: antidementia drugs, anti-rheumatic products for osteoarthritis, other vitamins, urologics for urinary incontinence, progestogens and estrogens in combination for menopause